BACKGROUND: @entity1 with @entity3620 ( @entity3620 ) usually die of progressive @entity66 . This report describes the results of a Phase III trial comparing maximum debulking surgery and postoperative @entity900 , @entity4020 , and @entity440 (CIT) immunochemotherapy with and without intraoperative photodynamic therapy (PDT) to determine (1) whether such a multimodal approach can be performed with minimum morbidity and mortality in @entity3620 ( @entity3620 ), and (2) whether first-generation (i.e., 630-nm laser light, @entity17654 ) intrapleural PDT impacts on local recurrence of survival. METHODS: From July 1993 to June 1996, 63 @entity1 with localized @entity3620 were randomized to either PDT or no PDT. The @entity5 of 15 @entity1 could not be debulked to 5 mm. @entity1 assigned to PDT (n = 25) and no PDT (n = 23) were similar with respect to age, sex, @entity5 volume, and histology. RESULTS: The type of resection (11 pleurectomies and 14 pneumonectomies vs. 12 pleurectomies and 11 pneumonectomies), length postoperative stay, and ICU time were comparable (PDT vs. no PDT). There was one operative death ( @entity548 ), and each group had two @entity292 . @entity86 divided @entity1 into the following categories: stage I: PDT, 2, no PDT, 2; stage II: PDT, 2, no PDT, 2; stage III, PDT, 21; no PDT, 17; stage IV, PDT, 0; no PDT, 2. Comparable numbers of CIT cycles were delivered. Median survival for the 15 non-debulked @entity1 was 7.2 months, compared to 14 months for the 48 @entity1 on protocol. There were no differences in median survival (14.4 vs. 14.1 months) or median progression-free time (8.5 vs. 7.7 months), and sites of first recurrence were similar. CONCLUSIONS: Aggressive multimodal therapy can be delivered for @entity1 with higher stage @entity3620 . First-generation PDT does not prolong survival or increase local control for @entity3620 .

Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity17654 :: ('MESH:D017323', 'Chemical') :: ['Photofrin II'] @entity66 :: ('MESH:D004194', 'Disease') :: ['local disease'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity3620 :: ('MESH:C562839', 'Disease') :: ['MPM', 'malignant pleural mesothelioma'] @entity292 :: ('MESH:D005402', 'Disease') :: ['bronchopleural fistulas'] @entity86 :: ('MESH:D019106', 'Disease') :: ['Postoperative staging'] @entity4020 :: ('3440', 'Gene') :: ['interferon alpha-2b']
@entity3620 :: (MESH:C562839,Disease) :: ['malignant pleural mesothelioma']
